In the Margins

Sequoia Fund's Valeant bet highlights concentration risks

November 2, 2015

By The Wall Street Journal

Concentrated bets on individual stocks raise issues for mutual funds and their investors—a matter highlighted last week at Sequoia Fund, one of the biggest investors in controversial drug maker Valeant Pharmaceuticals International Inc. Placing outsize bets on well-chosen stocks can lead to strong performance, but concentration increases the riskiness of a fund and raises questions about how much is too much. Read the original story from The Wall Street Journal.

 

 

Most Read

Top of the Agenda - Compensation
Fund CCOs continue to see pay increases

Mutual fund chief compliance officers saw notable increases in pay again in 2018, though they did not receive as big a pay bump as they did ...

10 Things
10 Things...to read in summer 2019

Hello, Summer 2019! Today's solstice marks the beginning of the season, and that—hopefully—means a slower pace for a few months. Trips to the beach, time on ...

A Seat at the Table
Invesco Funds board finalizes succession plans

The Invesco Funds board will name Christopher Wilson vice chairman at its June meeting, making him the heir apparent to long-serving independent Chair Bruce Crockett. Crockett ...